Flagler Health has raised $50 million in a Series B funding round to expand its artificial intelligence-based platform for treating musculoskeletal (MSK) diseases.
Bessemer Venture Partners led the round, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Ventures, and Offscript. The capital raised will be used by the company to scale its platform across MSK practices in the United States.
Flagler's technology supports various processes throughout the patient lifecycle, including triage, treatment management, billing, patient communication, and specialist referrals.
Flagler was founded by physicians and healthcare operators who personally encountered industry operational challenges. Their platform integrates clinical and administrative workflows through existing electronic health record systems.
Musculoskeletal diseases affect over half of the US adult population and generate annual healthcare costs exceeding $400 billion. Despite the large market size, MSK practices continue to face system fragmentation and high administrative burdens.
Physicians can spend nearly 75% of their time on non-revenue-generating tasks such as documentation, administrative procedures, and other operational duties. Flagler aims to solve these issues with an artificial intelligence layer that operates within the existing healthcare infrastructure.
The company asserts that providers can implement its technology without requiring additional logins, training, or workflow changes. The platform includes AI-driven revenue cycle management, prior authorization, billing, patient engagement, treatment management, and automated referral processing.
Artificial intelligence is capable of processing incoming electronic referrals and assisting patients with scheduling appointments. In three years, Flagler has expanded its presence to thousands of providers across more than 36 states. The company notes that its platform is utilized in various MSK practices and different electronic health record environments.
Flagler's technology was trained on a large dataset of patients with musculoskeletal diseases. This data is used to support workflows covering triage, treatment management, billing, and patient communication. The company's goal is to eliminate deficiencies in the underlying infrastructure supporting MSK care.
The company reports an average incremental annual revenue of $164,000 per provider. Furthermore, 87% of patients report improvements in pain, mood, sleep, or mobility. This approach allows Flagler to automate numerous interconnected processes rather than focusing solely on a single administrative task.
Albert Katz, CEO of Flagler Health, stated that his experience in MSK clinics revealed structural problems affecting physicians and practice margins. He emphasized that the issue extends beyond individual workflows.
The new capital will provide Flagler with the resources to expand its platform in the fragmented US healthcare market. It will also strengthen the company's ability to develop AI capabilities covering a broader range of operational processes.
Steve Kraus, Partner at Bessemer Venture Partners, noted that Flagler combines healthcare operations expertise, clinical expertise, and AI capabilities. He added that the company's early successes demonstrate potential in the MSK market.
This funding comes amid growing interest from healthcare providers in using AI that goes beyond simple documentation and transcription. Many new platforms target administrative burden, which takes time away from clinicians and increases operating costs. Flagler, however, employs a broader approach, connecting multiple processes around the patient, which may allow practices to automate referrals, communications, authorizations, billing, and follow-up visits through a unified operational layer.
Infinimmune has successfully raised $75 million in a Series A funding round, with the funds designated for advancing its therapeutic antibody pipeline. Regeneron Ventures and Playground Global participated as co-lead investors in this round, alongside several other existing investors.
The attracted capital follows significant progress made within Infinimmune's discovery platform and therapeutic programs. The biotechnology company plans to develop two leading candidates for the treatment of atopic dermatitis. Human trials for both programs are anticipated to commence in 2027.
This recent round reflects growing investor interest in human-derived antibody discovery technologies. This approach focuses on identifying antibodies naturally selected by the human immune system, which can then be optimized for therapeutic efficacy.
Infinimmune's Anthrobody platform analyzes millions of memory B cells across hundreds of different targets. This process allows for the identification of naturally associated human antibodies possessing beneficial therapeutic properties. Subsequently, the company utilizes the GLIMPSE antibody language models to guide the candidate optimization process.
This method aims to improve parameters such as specificity, potency, half-life, and developability. The company's lead candidate, IFX-101, targets interleukin-22 and is described as a potential first-class monoclonal antibody for atopic dermatitis. The second candidate, IFX-201, targets interleukin-13 and is being developed as a potentially superior treatment option.
Atopic dermatitis affects patients with chronic skin inflammation and recurring symptoms. While existing biologics have improved treatment options for many patients, some still face difficulties achieving sustained control over the condition. Infinimmune believes that enhancing potency and dosing convenience can address these limitations by aiming to create antibodies that maintain activity for longer periods.
In March 2026, Infinimmune entered into a collaboration agreement for discovering multi-target antibodies with Merck. This agreement includes upfront payments and potential milestone payments of up to approximately $838 million. The partnership focuses on Infinimmune's Anthrobody platform and GLIMPSE technology.
This collaboration further validates the company's human-centric strategy. The platform begins with antibodies generated naturally in response to human immune reactions. Infinimmune then applies computational and laboratory methods to enhance their therapeutic characteristics, which differs from methods heavily reliant on synthetic antibody libraries. The company believes its process can accelerate antibody discovery and optimization. Playground Global has supported Infinimmune since its inception.
Benjamin Kim noted that the platform possesses strong characteristics regarding potency, half-life, and developability. Regeneron Ventures also joined the round as a co-lead. This funding brings additional knowledge as Infinimmune prepares for clinical development.
The new capital will be used to prepare IFX-101 and IFX-201 for human studies expected in 2027. Clinical trials will allow for the first major assessment of these candidates in human patients, and their results may influence the company's overall development strategy. The company will also advance additional human-centric biology-based programs. Its platform is designed to identify antibodies against hundreds of potential therapeutic targets, opening opportunities to build a broader pipeline beyond atopic dermatitis. Thus, Infinimmune views its discovery technology as a long-term growth driver. The latest funding also strengthens its ability to scale the use of Anthrobody.
Multiplier has successfully raised $35 million in a Series B funding round. These funds are intended to scale its artificial intelligence-powered professional services platform. The General Partnership led this round, with existing investors Ribbit Capital and Lightspeed Venture Partners also participating.
The acquired investments will be directed towards acquiring additional specialized firms that provide professional services. Furthermore, they will help the company grow its technological and operational teams in response to the increasing demand for AI-based business services.
Multiplier operates on a permanent holding company model. By acquiring existing enterprises, the company allows them to retain their names, management, and a significant degree of autonomy. Instead of replacing people with artificial intelligence, Multiplier creates AI-based products that enhance efficiency and the quality of customer service.
Founder and CEO Noah Pepper stated in a company blog post that AI should serve as a tool to empower working professionals, not replace them. He believes that AI tools allow specialists to dedicate more time to tasks requiring judgment by eliminating routine work.
Multiplier integrates its engineering teams directly into the acquired firms. The company has also hired over 30 technologists whose work, together with subject matter experts, leads to the creation of AI tools tailored to the needs of specific businesses. Since the companies using this technology are not exclusively owned by third-party software developers, Multiplier employees have access to client and supplier databases, which, according to the founders, means 'access to clients, products, and processes.'
The company's model is focused on industries where growth is limited by expertise. Many professional service firms rely heavily on experienced practitioners and manage information through disparate systems. Multiplier believes that AI can automate preparatory and routine tasks, leaving final decisions to qualified specialists.
Since its inception, the company has completed eight acquisitions, five of which were closed within the last year. It also has four other firms that have signed letters of intent. In total, the company's network serves clients in more than 10 countries.
The latest investment coincides with the appointment of a senior executive. This person will oversee finance, operations, partnerships, personnel, and the expanding San Francisco office. The company believes this approach ensures more effective scaling while preserving valuable client relationships and professional experience over time.
Allen Shim, former CFO of Slack, now holds the positions of President and Chief Financial Officer at Multiplier. The company plans to use the funds to effectively build a scalable technological base, team, and operational process architecture. Shim previously led the successful initial public offering of Slack before its acquisition by Salesforce.
According to The General Partnership, accounting and other professional services markets continue to face capacity constraints despite growing demand. The investment firm is convinced that Multiplier's approach allows trusted specialists to serve more clients without compromising service quality.
The new capital will primarily go towards additional acquisitions and further development of proprietary AI solutions. Multiplier intends to develop its specialized firms and improve its technological capabilities. The company's investment approach differs from traditional 'buy and build' strategies, where founders of acquired companies are completely replaced after the acquisitions. Instead, founders remain in leadership roles, receiving continuous support in the form of long-term capital and operational management.
Cambridge-based company Qureight successfully secured $20 million in funding to improve the interpretation of chest scans using artificial intelligence. The firm develops AI imaging tools specifically for clinical trials related to the lungs and heart. The Series B funding round was spearheaded by Molten Ventures, with participation from existing backers such as Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension.
Dr Muhunthan Thillai, who does not possess an engineering background, co-founded Qureight in 2018 alongside Dr Alessandro Ruggiero. Thillai noted that this initial stage presented one of the most significant early challenges. The concept originated from his personal experience as a chest physician following a situation where he lacked confidence in interpreting a CT scan.
Thillai explained to Tech Funding News that the company began because there was a need to assist pharmaceutical companies in conducting superior clinical trials. Despite the difficulty of balancing founding duties, company growth, and patient care, Thillai continues to see patients part-time in Cambridge.
To address the technical expertise gap, Qureight recruited a CTO who previously served as the global head of platform at Hewlett Packard, a CMO who managed research at CMR Surgical, and a CSO with experience teaching machine learning at Imperial College London.
Qureight provides two distinct products for its pharmaceutical clientele. These tools reduce the time required for imaging decisions from approximately two weeks down to just 48 hours. The AI Lung model is capable of mapping airways and blood vessels, illustrating precisely how a medication influences disease progression.
Both products operate on a general-purpose foundation model focused on the chest. This allows disease-specific models to be developed in one or two months, significantly faster than the previous timeline of one year. The new investment will support the establishment of an in-house AI imaging laboratory.
The scope of Qureight's application extends to conditions including asthma, lung cancer, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. Currently, Qureight conducts worldwide trials in collaboration with AstraZeneca, Bristol Myers Squibb, and various biotechnology partners.
The market for lung and heart clinical trials is forecasted to reach $27.5 billion by 2030, exhibiting an annual growth rate of 6.9%. A primary European competitor is Oxford’s Brainomix, which utilizes an FDA-cleared e-Lung platform for pulmonary fibrosis trials. However, the operational overlap between the two entities is limited: Brainomix focuses on selling diagnostic software to hospitals, whereas Qureight concentrates on trial design and imaging contract research. Notably, the Brainomix platform was recently selected by Boehringer Ingelheim for a Phase 3 trial.
Qureight initially approached Molten two years prior but was declined. This time, three lead investors submitted term sheets within a six-week period, and the company had the potential to raise a larger sum. Nevertheless, Qureight opted for Molten due to the established relationship and the desire to anchor the funding round with a London-based fund rather than pursuing competing US offers.
Dr Inga Deakin, the Molten partner joining Qureight’s board, commented that Qureight exemplifies how AI, when supported by real-world data, can expedite discovery processes and revolutionize clinical research. Looking ahead, Qureight intends to double its staff to 100 by December, establish a second office in London next month, and commence trials for asthma, lung cancer, and pulmonary hypertension before the year concludes.
